Seeking Alpha
 

Urologix, Inc. (ULGX)

- OTCQB
  • Mon, Jan. 12, 12:08 PM
    • Urologix (OTCQB:ULGX) reports fiscal Q2 results on February 5 after the close. The conference call will begin at 4:00 pm CT/5:00 pm ET.
    • On a preliminary basis, revenues for the quarter were $3.1M.
    | Comment!
  • Nov. 4, 2014, 5:40 PM
    | Comment!
  • Aug. 19, 2014, 5:17 PM
    • Urologix (ULGX) fiscal Q4 and full year results:
    • Q4: Revenues: $3.3M (-21.3%); Operating Expenses: $5.0M (+56.6%); Net Loss: ($3.5M) (-182.7%); Loss Per Share: ($0.17) (-183.3%); Quick Assets: $0.7M (-68.6%).
    • Fiscal 2014: Revenues: $14.2M (-14.2%); Operating Expenses: $13.0M (+7.6%); Net Loss: ($7.6M) (-77.3%); Loss Per Share: ($0.36) (-71.4%); Cash Burn: ($1.5M) (+21.9%).
    • No financial guidance given.
    | Comment!
  • May. 2, 2013, 6:26 AM
    Urologix (ULGX): Q1 EPS of -$0.05 beats by $0.01. Revenue of $4.1M beats by $0.25M. (PR)
    | Comment!
  • Feb. 6, 2013, 6:23 AM
    Urologix (ULGX): FQ2 EPS of -$0.05 in-line. Revenue of $4.4M (+9.7% Y/Y) beats by $0.4M. (PR)
    | Comment!
  • Sep. 6, 2011, 2:30 PM
    Urologix (ULGX +27%) soars after announcing it's signed an exclusive worldwide license to manufacture and market Medtronic's (MDT +0.2%) Prostiva RF Therapy System for the treatment of BPH.
    | Comment!
ULGX vs. ETF Alternatives
Company Description
Urologix, Inc. develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement also known as benign prostatic hyperplasia (BPH).